Table 3.
Comparison of Seroconversion Rates of Influenza Strains Between PCV13+QIV and Placebo+QIV (Evaluable Immunogenicity Population).
| Vaccine Sequence (as Randomized) |
|||||
|---|---|---|---|---|---|
|
PCV13+QIV, placebo Na = 427 |
Placebo+QIV, PCV13 Na = 430 |
||||
| Strain | nb | % (95% CI)c | nb | % (95% CI)c | Differenced (95% CI)e |
| A/H1N1 | 125 | 29.3 (25.0–33.8) | 104 | 24.2 (20.2–28.5) | 5.1 (−0.9 to 11.0) |
| A/H3N2 | 119 | 27.9 (23.7–32.4) | 136 | 31.6 (27.3–36.3) | −3.8 (−9.9 to 2.4) |
| B/Brisbane | 91 | 21.3 (17.5–25.5) | 96 | 22.3 (18.5–26.6) | −1.0 (−6.6 to 4.5) |
| B/Massachusetts | 99 | 23.2 (19.3–27.5) | 106 | 24.7 (20.6–29.0) | −1.5 (−7.2 to 4.3) |
HAI = hemagglutination inhibition assay; PCV13 = 13-valent pneumococcal conjugate vaccine; QIV = quadrivalent inactivated influenza vaccine.
Underlined vaccine names indicate which immune response data for each study group are presented for comparison in the table.
aN = Number subjects with known values.
bn = Number of subjects with the given characteristic.
cExact 2-sided CI (Clopper and Pearson) based on the observed proportion of subjects.
dDifference in proportions (PCV13+QIV/placebo – placebo+QIV/PCV13) expressed as a percentage.
eExact 2-sided CI and corresponding P value (based on Chan and Zhang) for the difference in proportions (PCV13+QIV/placebo – placebo+QIV/PCV13) expressed as a percentage.